CYP3A4/5 Recessive Variant and Medication Management

Primary Clinical Concerns

The American College of Cardiology and other guideline societies recommend avoiding strong CYP3A4 inhibitors and inducers in patients with reduced CYP3A4/5 activity to prevent dangerous drug interactions that can cause life-threatening toxicity or treatment failure 1
The National Comprehensive Cancer Network recommends that patients with reduced CYP3A4/5 activity should avoid strong CYP3A4 inhibitors such as azole antifungals, macrolide antibiotics, and HIV protease inhibitors to prevent severe toxicity 2, 3

The National Comprehensive Cancer Network recommends avoiding strong CYP3A4 inhibitors such as ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, ritonavir, nelfinavir, saquinavir, atazanavir, indinavir, and nefazodone in patients with reduced CYP3A4/5 activity 2, 3
The National Comprehensive Cancer Network recommends avoiding strong CYP3A4 inducers such as phenytoin, carbamazepine, phenobarbital, rifampin, rifabutin, rifapentin, and St. John's wort in patients with reduced CYP3A4/5 activity 2, 4

The American College of Cardiology recommends that patients with reduced CYP3A4/5 activity who require tyrosine kinase inhibitors such as imatinib, dasatinib, and nilotinib should have their doses adjusted and be monitored intensively 1, 5, 6
The National Comprehensive Cancer Network recommends that patients with reduced CYP3A4/5 activity who require taxanes such as docetaxel and paclitaxel should have their doses adjusted and be monitored intensively 7, 1

The National Comprehensive Cancer Network recommends that the combination of aprepitant with pimozide, terfenadine, astemizole, or cisapride is absolutely contraindicated due to the risk of fatal cardiac arrhythmias 7

The American College of Cardiology recommends a step-wise approach to managing patients with reduced CYP3A4/5 activity, including medication reconciliation, risk stratification, and intervention strategies 1
The National Comprehensive Cancer Network recommends that patients with reduced CYP3A4/5 activity should be monitored for signs of toxicity or treatment failure, and that dose adjustments should be made based on clinical response 1, 4

The American College of Cardiology recommends that oral vs. IV formulations should be considered when available, as oral drugs are more affected by CYP3A4 interactions due to first-pass metabolism 1, 7
The National Comprehensive Cancer Network recommends that grapefruit juice should be avoided in patients with reduced CYP3A4/5 activity, as it is a potent CYP3A4 inhibitor 4, 3